A US jury decision in a long-running ADC patent dispute between Seagen and Daiichi Sankyo has found in favor of the US firm. But Daiichi has vowed to challenge the outcome while its motion to question the validity of the original patent on which the case is based has also just been granted, meaning the final impact remains uncertain.
A jury in the US District Court of Eastern District of Texas decided on 8 April that the sale in the US of Daiichi Sankyo Co., Ltd./AstraZeneca PLC’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan; DS-8201) infringes Seagen Inc. ’s US patent 10,808,039.
The decision awarded damages of $41